Nucleix secures $55M in funding for lung cancer test

2020 06 01 18 51 2022 Cancer Lung 400

Liquid biopsy company Nucleix has secured $55 million to advance Lung EpiCheck, an early detection lung cancer test based on methylation technology.

Nucleix will use the financing to continue to advance its methylation technology and the blood-based assay. The test analyzes subtle, disease-specific changes in DNA methylation markers in patients, specifically current and former smokers.

Page 1 of 6
Next Page